Abstract
Colonic carcinogenesis is characterized by progressive accumulations of genetic and epigenetic derangements. These molecular events are accompanied by histological changes that progress from mild cryptal architectural abnormalities in small adenomas to eventual invasive cancers. The transition steps from normal colonic epithelium to small adenomas are little understood. In experimental models of colonic carcinogenesis aberrant crypt foci (ACF), collections of abnormal appearing colonic crypts, are the earliest detectable abnormality and precede adenomas. Whether in fact ACF are precursors of colon cancer, however, remains controversial. Recent advances in magnification chromoendoscopy now allow these lesions to be identified in vivo and their natural history ascertained.
While increasing lines of evidence suggest that dysplastic ACF harbor a malignant potential, there are few prospective studies to confirm causal relationships and supporting epidemiological studies are scarce. It would be very useful, for example, to clarify the relationship of ACF incidence to established risks for colon cancer, including age, smoking, sedentary lifestyle, and Western diets. In experimental animal models, carcinogens dose-dependently increase ACF, whereas most chemopreventive agents reduce ACF incidence or growth. In humans, however, few agents have been validated to be chemopreventive of colon cancer. It remains unproven, therefore, whether human ACF could be used as reliable surrogate markers of efficacy of chemopreventive agents. If these lesions could be used as reliable biomarkers of colon cancer risk and their reductions as predictors of effective chemopreventive agents, metrics to quantify ACF could greatly facilitate the study of colonic carcinogenesis and chemoprevention.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal, A., Murray, T., Samuels, A., Gha-foor, A., Ward, E., and Thun, M. J. (2003) Cancer statistics 2003. CA Cancer J Clin. 53, 5–26.
Fernandez, E., Gallus, S., La Vecchia, C., Talamini, R., Negri, E., and Franceschi, S. (2004) Family history and environmental risk factors for colon cancer. Cancer Epidemiol Biomarkers Prev. 13, 658–661.
Lieberman, D. A., Prindiville, S., Weiss, D. G., and Willett, W. (2003) Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA 290, 2959–2967.
Emmons, K. M., McBride, C. M., Puleo, E., Pollak, K. I., Clipp, E., Kuntz, K., Marcus, B. H., Napolitano, M., Onken, J., Far-raye, F., and Fletcher, R. (2005) Project PREVENT: a randomized trial to reduce multiple behavioral risk factors for colon cancer. Cancer Epidemiol Biomarkers Prev. 14, 1453–1459.
Schatzkin, A. (2000) Intermediate markers as surrogate endpoints in cancer research. Hematol Oncol Clin North Am. 14, 887–905.
Winawer, S. J., Zauber, A. G., Ho, M. N., O'Brien, M. J., Gottlieb, L. S., Sternberg, S. S., Waye, J. D., Schapiro, M., Bond, J. H., Panish, J. F., and et al. (1993) Prevention of colorectal cancer by colonoscopic polypec-tomy. The National Polyp Study Workgroup. N Engl J Med. 329, 1977–1981.
Kinzler, K. W. and Vogelstein, B. (1996) Lessons from hereditary colorectal cancer. Cell 87, 159–170.
Winawer, S. J. (2005) Screening of color-ectal cancer. Surg Oncol Clin N Am. 14, 699–722.
Hurlstone, D. P., Fujii, T., and Lobo, A. J. (2002) Early detection of colorectal cancer using high-magnification chromoscopic colonoscopy. Br J Surg. 89, 272–282.
Hurlstone, D. P., Karajeh, M., Sanders, D. S., Drew, S. K., and Cross, S. S. (2005) Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia. Am J Gastroenterol. 100, 1283–1289.
Ross, A. S. and Waxman, I. (2006) Flat and depressed neoplasms of the colon in Western populations. Am J Gastroenterol. 101, 172–180.
Srivastava, S., Verma, M., and Henson, D. E. (2001) Biomarkers for early detection of colon cancer. Clin Cancer Res. 7, 1118–1126.
Takayama, T., Katsuki, S., Takahashi, Y., Ohi, M., Nojiri, S., Sakamaki, S., Kato, J., Kogawa, K., Miyake, H., and Niitsu, Y. (1998) Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 339, 1277–1284.
Takayama, T., Ohi, M., Hayashi, T., Miya-nishi, K., Nobuoka, A., Nakajima, T., Satoh, T., Takimoto, R., Kato, J., Sakamaki, S., and Niitsu, Y. (2001) Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial ade-nomatous polyposis. Gastroenterology 121, 599–611.
Bird, R. P. (1987) Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 37, 147–151.
McLellan, E. A. and Bird, R. P. (1988) Aberrant crypts: potential preneoplas-tic lesions in the murine colon. Cancer Research 48, 6187–6192.
Corpet, D. E. and Tache, S. (2002) Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 43, 1–21.
Roncucci, L., Modica, S., Pedroni, M., Tamassia, M. G., Ghidoni, M., Losi, L., Fante, R., Di Gregorio, C., Manenti, A., Gafa, L., and Ponz de Leon, M. (1998) Aberrant crypt foci in patients with colorectal cancer. Br J Cancer 77, 2343–2348.
Yokota, T., Sugano, K., Kondo, H., Saito, D., Sugihara, K., Fukayama, N., Ohkura, H., Ochiai, A., and Yoshida, S. (1997) Detection of aberrant crypt foci by magnifying colonoscopy. Gastrointest Endosc. 46, 61–65.
Hurlstone, D. P. and Cross, S. S. (2005) Role of aberrant crypt foci detected using high-magnification-chromoscopic colonos-copy in human colorectal carcinogenesis. J Gastroenterol Hepatol. 20, 173–181.
Seike, K., Koda, K., Oda, K., Kosugi, C., Shimizu, K., Nishimura, M., Shioiri, M., Takano, S., Ishikura, H., and Miyazaki, M. (2006) Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am J Gastroenterol. 101, 1362–1369.
Roncucci, L., Stamp, D., Medline, A., Cul-len, J. B., and Bruce, W. R. (1991) Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol. 22, 287–294.
Rao, A. V., Janezic, S. A., Friday, D., and Kendall, C. W. (1992) Dietary cholesterol enhances the induction and development of colonic preneoplastic lesions in C57BL/6J and BALB/cJ mice treated with azoxymeth-ane. Cancer Lett. 63, 249–257.
Kendall, C. W., Koo, M., Sokoloff, E., and Rao, A. V. (1992) Effect of dietary oxidized cholesterol on azoxymethane-induced colonic preneoplasia in mice. Cancer Lett. 66, 241–248.
Pretlow, T. P., Barrow, B. J., Ashton, W. S., O'Riordan, M. A., Pretlow, T. G., Jurcisek, J. A., and Stellato, T. A. (1991) Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res. 51, 1564–1567.
Roncucci, L., Pedroni, M., Fante, R., Di Gregorio, C., and Ponz de Leon, M. (1993) Cell kinetic evaluation of human colonic aberrant crypts. (Colorectal Cancer Study Group of the University of Modena and the Health Care District 16, Modena, Italy). Cancer Res. 53, 3726–3729.
Di Gregorio, C., Losi, L., Fante, R., Mod-ica, S., Ghidoni, M., Pedroni, M., Tamassia, M. G., Gafa, L., Ponz de Leon, M., and Roncucci, L. (1997) Histology of aberrant crypt foci in the human colon. Histopathology 30, 328–334.
Shpitz, B., Bomstein, Y., Mekori, Y., Cohen, R., Kaufman, Z., Neufeld, D., Galkin, M., and Bernheim, J. (1998) Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. Hum Pathol. 29, 469–475.
Bouzourene, H., Chaubert, P., Seelentag, W., Bosman, F. T., and Saraga, E. (1999) Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum Pathol. 30, 66–71
Yamada, Y., Yoshimi, N., Hirose, Y., Kawabata, K., Matsunaga, K., Shimizu, M., Hara, A., and Mori, H. (2000) Frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res. 60, 3323–3327.
Yamada, Y., Yoshimi, N., Hirose, Y., Mat-sunaga, K., Katayama, M., Sakata, K., Shimizu, M., Kuno, T., and Mori, H. (2001) Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res. 61, 1874–1878.
Paulsen, J. E., Loberg, E. M., Olstorn, H. B., Knutsen, H., Steffensen, I. L., and Alexander, J. (2005) Flat dysplastic aberrant crypt foci are related to tumorigenesis in the colon of azoxymethane-treated rat. Cancer Res. 65, 121–129.
Caderni, G., Femia, A. P., Giannini, A., Favuzza, A., Luceri, C., Salvadori, M., and Dolara, P. (2003) Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res. 63, 2388–2392.
Vaccina, F., Scorcioni, F., Pedroni, M., Tamassia, M. G., De Leon, M. P., De Pol, A., Marzona, L., and Roncucci, L. (1998) Scanning electron microscopy of aberrant crypt foci in human colorectal mucosa. Anticancer Res. 18, 3451–3456.
Otori, K., Sugiyama, K., Hasebe, T., Fuku-shima, S., and Esumi, H. (1995) Emergence of adenomatous aberrant crypt foci (ACF) from hyperplastic ACF with concomitant increase in cell proliferation. Cancer Research 55, 4743–4746.
Ochiai, M., Watanabe, M., Nakanishi, M., Taguchi, A., Sugimura, T., and Nakagama, H. (2005) Differential staining of dysplas-tic aberrant crypt foci in the colon facilitates prediction of carcinogenic potentials of chemicals in rats. Cancer Lett. 220, 67–74.
Losi, L., Roncucci, L., di Gregorio, C., de Leon, M. P., and Benhattar, J. (1996) K-ras and p53 mutations in human colorectal aberrant crypt foci. J Pathol. 178, 259–263.
Otori, K., Konishi, M., Sugiyama, K., Hasebe, T., Shimoda, T., Kikuchi-Yanos-hita, R., Mukai, K., Fukushima, S., Miyaki, M., and Esumi, H. (1998) Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue. Cancer 83, 896–900.
Greenspan, E. J., Cyr, J. L., Pleau, D. C., Levine, J., Rajan, T. V., Rosenberg, D. W., and Heinen, C. D. (2007) Microsat-ellite instability in aberrant crypt foci from patients without concurrent colon cancer. Carcinogenesis 28, 769–776.
Cheng, L. and Lai, M. D. (2003) Aberrant crypt foci as microscopic precursors of colorectal cancer. World J Gastroenterol. 9, 2642–2649.
Pretlow, T. P. and Pretlow, T. G. (2005) Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim Bio-phys Acta 1756, 83–96.
Alrawi, S. J., Schiff, M., Carroll, R. E., Dayton, M., Gibbs, J. F., Kulavlat, M., Tan, D., Berman, K., Stoler, D. L., and Anderson, G. R. (2006) Aberrant crypt foci. Antican-cer Res. 26, 107–119.
Gupta, A. K., Pretlow, T. P., and Schoen, R. E. (2007) Aberrant crypt foci: what we know and what we need to know. Clin Gas-troenterol Hepatol. 5, 526–533.
Luo, L., Shen, G. Q., Stiffler, K. A., Wang, Q. K., Pretlow, T. G., and Pretlow, T. P. (2006) Loss of heterozygosity in human aberrant crypt foci (ACF), a putative precursor of colon cancer. Carcinogenesis 27, 1153–1159.
Augenlicht, L. H., Richards, C., Corner, G., and Pretlow, T. P. (1996) Evidence for genomic instability in human colonic aberrant crypt foci. Oncogene 12, 1767–1772
Heinen, C. D., Shivapurkar, N., Tang, Z., Groden, J., and Alabaster, O. (1996) Microsatellite instability in aberrant crypt foci from human colons. Cancer Res. 56, 5339–5341.
Gryfe, R., Kim, H., Hsieh, E. T., Aronson, M. D., Holowaty, E. J., Bull, S. B., Red-ston, M., and Gallinger, S. (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 342, 69–77.
Polakis, P. (1999) The oncogenic activation of beta-catenin. Curr Opin Genet Dev. 9, 15–21.
Giles, R. H., van Es, J. H., and Clevers, H. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653, 1–24.
Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. N., Vogelstein, B., and Kinzler, K. W. (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359, 235–237.
Iwamoto, M., Ahnen, D. J., Franklin, W. A., and Maltzman, T. H. (2000) Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis 21, 1935–1940.
Jen, J., Powell, S. M., Papadopoulos, N., Smith, K. J., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. (1994) Molecular determinants of dysplasia in colorectal lesions. :Cancer Res. 54, 5523–5526.
Smith, A. J., Stern, H. S., Penner, M., Hay, K., Mitri, A., Bapat, B. V., and Gallinger, S. (1994) Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 54, 5527–5530.
Shivapurkar, N., Tang, Z., Ferreira, A., Nasim, S., Garett, C., and Alabaster, O. (1994) Sequential analysis of K-ras mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in Fischer-344 rats on high-risk diet. Carcino-genesis 15, 775–778.
Cohen, G., Mustafi, R., Chumsangsri, A., Little, N., Nathanson, J., Cerda, S., Jaga-deeswaran, S., Dougherty, U., Joseph, L., Hart, J., Yerian, L., Tretiakova, M., Yuan, W., Obara, P., Khare, S., Sinicrope, F. A., Fichera, A., Boss, G. R., Carroll, R., and Bissonnette, M. (2006) Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res. 66, 5656–5664.
Fichera, A., Little, N., Jagadeeswaran, S., Dougherty, U., Sehdev, A., Mustafi, R., Cerda, S., Yuan, W., Khare, S., Tretiakova, M., Gong, C., Tallerico, M., Cohen, G., Joseph, L., Hart, J., Turner, J. R., and Bis-sonnette, M. (2007) Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcino-genesis. Cancer Res. 67, 827–835.
Adler, D. G., Gostout, C. J., Sorbi, D., Bur-gart, L. J., Wang, L., and Harmsen, W. S. (2002) Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest Endosc. 56, 657–662.
Yamashita, N., Minamoto, T., Ochiai, A., Onda, M., and Esumi, H. (1995) Frequent and characteristic K-ras activation in aberrant crypt foci of colon. Is there preference among K-ras mutants for malignant progression? Cancer 75, 1527–1533.
Siu, I. M., Pretlow, T. G., Amini, S. B., and Pretlow, T. P. (1997) Identification of dys-plasia in human colonic aberrant crypt foci. Am J Pathol. 150, 1805–1813.
Siu, I. M., Robinson, D. R., Schwartz, S., Kung, H. J., Pretlow, T. G., Petersen, R. B., and Pretlow, T. P. (1999) The identification of monoclonality in human aberrant crypt foci. Cancer Res. 59, 63–66.
Gold, P., Shuster, J., and Freedman, S. O. (1978) Carcinoembryonic antigen (CEA) in clinical medicine: historical perspectives, pitfalls and projections. Cancer 42, 1399–1405.
Pretlow, T. P., Roukhadze, E. V., O'Riordan, M. A., Chan, J. C., Amini, S. B., and Stel-lato, T. A. (1994) Carcinoembryonic antigen in human colonic aberrant crypt foci. Gastroenterology 107, 1719–1725.
Miyoshi, Y., Ando, H., Nagase, H., Nishisho, I., Horii, A., Miki, Y., Mori, T., Utsunomiya, J., Baba, S., Petersen, G., and et al. (1992) Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci USA 89, 4452–4456.
Qi, J., Zhu, Y. Q., Luo, J., and Tao, W. H. (2006) Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol. 12, 7113–7117.
Samowitz, W. S., Powers, M. D., Spirio, L. N., Nollet, F., van Roy, F., and Slattery, M. L. (1999) b-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res. 59, 1442–1444.
Howe, L. R., Subbaramaiah, K., Chung, W. J., Dannenberg, A. J., and Brown, A. M. (1999) Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res. 59, 1572–1577.
Bissonnette, M., Khare, S., von Lintig, F. C., Wali, R. K., Nguyen, L., Zhang, Y., Hart, J., Skarosi, S., Varki, N., Boss, G. R., and Brasitus, T. A. (2000) Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1. Cancer Res. 60, 4602–4609.
Eisinger, A. L., Nadauld, L. D., Shelton, D. N., Peterson, P. W., Phelps, R. A., Chidester, S., Stafforini, D. M., Prescott, S. M., and Jones, D. A. (2006) The adenoma-tous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid. J Biol Chem. 281, 20474–20482.
Bjerknes, M., Cheng, H., Hay, K., and Gallinger, S. (1997) APC mutation and the crypt cycle in murine and human intestine. Am J Pathol. 150, 833–839.
Otori, K., Oda, Y., Sugiyama, K., Hasebe, T., Mukai, K., Fujii, T., Tajiri, H., Yoshida, S., Fukushima, S., and Esumi, H. (1997) High frequency of K-ras mutations in human colorectal hyperplastic polyps. Gut 40, 660–663.
Hill, M. J., Morson, B. C., and Bussey, H. J. (1978) Aetiology of adenoma—carcinoma sequence in large bowel. Lancet 1, 245–247.
Day, D. W. and Morson, B. C. (1978) The adenoma-carcinoma sequence. Major Probl Pathol. 10, 58–71.
Granqvist, S. (1981) Distribution of polyps in the large bowel in relation to age. A colonoscopic study. Scand J Gastroenterol. 16, 1025–1031.
Devesa, S. S. and Chow, W. H. (1993) Variation in colorectal cancer incidence in the United States by subsite of origin. Cancer 71, 3819–3826.
Konstantakos, A. K., Siu, I. M., Pretlow, T. G., Stellato, T. A., and Pretlow, T. P. (1996) Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer. Gastroenterology 111, 772–777.
Boland, C. R., Sinicrope, F. A., Brenner, D. E., and Carethers, J. M. (2000) Colorectal cancer prevention and treatment. Gastroen-terology 118, 115–128.
Stevens, R. G., Swede, H., Heinen, C. D., Jablonski, M., Grupka, M., Ross, B., Parente, M., Tirnauer, J. S., Giardina, C., Rajan, T. V., Rosenberg, D. W., and Levine, J. (2007) Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett. 248, 262–268.
Rudolph, R. E., Dominitz, J. A., Lampe, J. W., Levy, L., Qu, P., Li, S. S., Lampe, P. D., Bronner, M. P., and Potter, J. D. (2005) Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev. 14, 605–608.
Armitage, P. and Doll, R. (1954) The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 8, 1–12.
Papanikolaou, A., Wang, Q. S., Papanikolaou, D., Whiteley, H. E., and Rosenberg, D. W. (2000) Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 21, 1567–1572.
Nambiar, P. R., Nakanishi, M., Gupta, R., Cheung, E., Firouzi, A., Ma, X. J., Flynn, C., Dong, M., Guda, K., Levine, J., Raja, R., Achenie, L., and Rosenberg, D. W. (2004) Genetic signatures of high-and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer. Cancer Res. 64, 6394–6401.
Shpitz, B., Klein, E., Buklan, G., Neufeld, D., Nissan, A., Freund, H. R., Grankin, M., and Bernheim, J. (2003) Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut 52, 1598–1601.
Moxon, D., Raza, M., Kenney, R., Ewing, R., Arozullah, A., Mason, J. B., and Carroll, R. E. (2005) Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin Gastroenterol Hepatol. 3, 271–278.
Slaughter, D. P., Southwick, H. W., and Smejkal, W. (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6, 963–968.
Benner, S. E., Hong, W. K., Lippman, S. M., Lee, J. S., and Hittelman, W. M. (1992) Intermediate biomarkers in upper aerod-igestive tract and lung chemoprevention trials. J Cell Biochem Suppl. 16G, 33–38.
Wattenberg, L. W. (1985) Chemopreven-tion of cancer. Cancer Res. 45, 1–8.
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., Steinbach, G., and Schilsky, R. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 348, 883–890.
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., Snover, D. C., Church, T. R., Allen, J. I., Beach, M., Beck, G. J., Bond, J. H., Byers, T., Greenberg, E. R., Mandel, J. S., Marcon, N., Mott, L. A., Pearson, L., Saibil, F., and van Stolk, R. U. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 348, 891–899.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Khare, S., Chaudhary, ., Bissonnette, M., Carroll, R. (2009). Aberrant Crypt Foci in Colon Cancer Epidemiology. In: Verma, M. (eds) Cancer Epidemiology. Methods in Molecular Biology, vol 472. Humana Press. https://doi.org/10.1007/978-1-60327-492-0_17
Download citation
DOI: https://doi.org/10.1007/978-1-60327-492-0_17
Publisher Name: Humana Press
Print ISBN: 978-1-60327-491-3
Online ISBN: 978-1-60327-492-0
eBook Packages: Springer Protocols